S Kossatz J Grandke P Couleaud A Latorre
 S. Kossatz, J. Grandke, P. Couleaud, A. Latorre, A. Aires, K. Crosbie-Staunton, R. Ludwig, H. Dähring, V. Ettelt, A. Lazaro-Carrillo, Eﬃcient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery, Breast Cancer Res. 17 (2015) 66.
 V.T. Trang, N. Van Quy, T.Q. Huy, L.M. Tung, A.-T. Le, V.N. Phan, Preparation and characterization of Aminosilane-functionalized magnetic antibody conjugates for bacterial recognition and capture, IEEE Trans. Magn. 54 (2018) 1–4.  Z. Sharafi, B. Bakhshi, J. Javidi, S. Adrangi, Synthesis of silica-coated iron oxide nanoparticles: preventing aggregation without using additives or seed
 S. Moore, M.A. Cobleigh, Targeting metastatic and advanced breast cancer, Semin. Oncol. Nurs. 23 (2007) 37–45.  M.G. Anhorn, S. Wagner, J. Kreuter, K. Langer, H. von Briesen, Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles, Bioconjug. Chem. 19 (2008)
S. Fernández, H. Saade, R.G. López, Chitosan-coated magnetic nanoparticles pre-pared in one-step by precipitation in a high-aqueous phase content reverse Journal of Magnetism and Magnetic Materials 490 (2019) 165479
 M.A. Zulfikar, S. Afrita, D. Wahyuningrum, M. Ledyastuti, Preparation of Fe3O4-chitosan hybrid nano-particles used for humic GS-9620 adsorption, Environ. Nanotechnol. Monit. Manage. 6 (2016) 64–75.
 N. Arsalani, H. Fattahi, M. Nazarpoor, Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent, eXPRESS Polym. Lett. 4 (2010) 329–338.
 M. Jafarzadeh, E. Soleimani, H. Sepahvand, R. Adnan, Synthesis and character-ization of fluconazole-functionalized magnetic nanoparticles as a catalyst for the synthesis of 3-aryl and 3-amino-imidazo [1, 2-a] pyridines, RSC Adv. 5 (2015)
M. Marvibaigi, N. Amini, Synthesis, characterization and in vitro evaluation of exquisite targeting SPIONs–PEG–HER in HER2+ human breast cancer cells, Nanotechnology 27 (2016) 105601.
Contents lists available at ScienceDirect
Colloids and Surfaces B: Biointerfaces
journal homepage: www.elsevier.com/locate/colsurfb
Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 T (LA-SN38) conjugate in a murine model of colorectal cancer
Guilin Chenga,1, Xiaomin Zhang b,1, Yidan Chenc, Robert J. Leed, Jiangfeng Wanga, Ju Yaob, Yingxin Zhangb, Cheng Zhange, Kaifeng Wangf, , Bo Yub, a Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, PR China b Hangzhou PushKang Biotechnology Co., Ltd., Hangzhou 310030, Zhejiang, PR China c Hangzhou Cancer Institution, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang, PR China d Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA e Class 8 of Shaoxing No. 1 High School, Shaoxing 312000, Zhejiang, PR China f Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang, PR China
Linoleic acid conjugated SN38
Biodegradable polymeric nanoparticles (NPs) have been used frequently as nanocarriers for anticancer drugs. Linoleic acid conjugated SN38 (LA-SN38)-loaded NPs (EBNPs) were developed using biodegradable poly (ethylene oxide)-poly (butylene oxide) (PEO-PBO) diblock copolymer by titration hydration method without using a toxic organic solvent. The EBNPs had high drug loading efficiency and entrapment efficiency for LA-SN38, at 7.53% and 93.55%, respectively. The polydispersity index (PDI) and average diameter were 0.173 ± 0.019 and 226.1 ± 1.2 nm, respectively. The transmission electron microscope (TEM) image pre-sented that the NPs were homogeneous in size and had spherical structures. In vitro study showed the release behavior of EBNPs was slow and sustained. Furthermore, cytotoxicity and apoptosis assay proved that EBNPs were more effective in growth inhibition of human colon cancer cells. Cell uptake experiments further de-monstrated that EBNPs could avoid the phagocytosis by macrophages and promote the uptake by cancer cells. In vivo, EBNPs had prolonged blood circulation time and tumor selectivity in biodistribution. The tumor inhibitory rate of EBNPs was higher compared to SNPs group and CPT-11group (P < 0.01), and the drug did not show significant systemic toxicity at the tested dose. These results indicated that EBNPs are a promising candidate for delivery of LA-SN38 to treat colorectal cancer.